Lung Cancer

In a phase III study, the administration of pembrolizumab with chemotherapy provided progression-free survival and overall survival benefits with a satisfactory safety profile compared to placebo in previously untreated patients with metastatic squamous non-small-cell lung cancer. The KEYNOTE-407 phase III study assessed the long-term survival outcomes in metastatic squamous non-small-cell lung cancer (NSCLC) patients treated...

Trastuzumab deruxtecan demonstrated an acceptable safety profile and was associated with a clinically significant objective response rate in patients with HER2-mutant metastatic non-small-cell lung cancer in a phase II study. Human epidermal growth factor receptor (HER2) mutations are present in a small number of non-squamous non-small-cell lung cancer (NSCLC) patients. Trastuzumab deruxtecan (T-DXd) is approved...

The spatial distribution of CD103+CD8+ tissue-resident memory T cells is a prognostic biomarker for non-small cell lung cancer, according to the results of a recent cohort study. Tissue-resident memory T cells (TRM) are a special population of immune cells that reside in solid[spacer height=”10px”]tumors and their microenvironment. Although emerging evidence has linked these cells to[spacer...

Serum levels of 8-hydroxy-deoxyguanosine were positively correlated with ionizing radiation in non-small cell lung cancer, with possible prognostic significance in the squamous pathology subgroup in an observational study. Ionizing radiation is associated with DNA damage, which can be direct or indirect, as with the production of reactive oxygen species (ROS). The most common ROS-induced base...

The long non-coding RNA LINC02159 promotes non-small cell lung cancer progression through ALYREF/YAP1 signaling, according to the results of a recent cell culture study. Lung cancer is the leading cause of cancer-related deaths globally. Long non-coding RNAs (lncRNAs) have recently emerged as key regulators in cancer development and progression, including non-small cell lung cancer (NSCLC),...

Amivantamab plus lazertinib shows durable clinical activity in osimertinib-relapsed, epidermal growth factor receptor-mutated advanced non-small cell lung cancer in a phase I study. Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), is the current standard-of-care treatment for EGFR-mutated non-small cell lung cancer (NSCLC). However, resistance is common, and there are no...

Circulating tumor DNA response to pembrolizumab can identify patients with molecular disease progression needing treatment intensification, according to the results of a phase II/III clinical trial. Circulating tumor DNA (ctDNA) has demonstrated promise in identifying primary resistance to immunotherapy. Concerning non-small cell lung cancer (NSCLC), where pembrolizumab and combination pembrolizumab–carboplatin–taxane/pemetrexed are the first-line options, it...

A recent literature review identifies promising therapeutic agents that have shifted the non-small cell lung cancer treatment paradigm. Lung cancer is the leading cause of cancer mortality worldwide. Research is rapidly evolving regarding the treatment of non-small cell lung cancer (NSCLC) with biomarker-driven targeted therapy and immunotherapy using checkpoint inhibitors.  A review of phase III...

PLCOm2012 models have higher sensitivity than USPSTF criteria, with no difference by Indigenous classification Two versions of the PLCOm2012 risk‐prediction model (based on the 2012 Prostate, Lung, Colorectal, and Ovarian [PLCO] Cancer Screening Trial), with and without a predictor for race, have high sensitivities for lung cancer, according to a study published online Oct. 9...